Amy Grove, Volunteer at Pennsylvania Cancer Coalition, shared Cancer Precision Medicine Commons’s on LinkedIn, adding:
“As someone diagnosed almost 8 years ago with Stage 4 Squamous Non-Small Cell Lung Cancer, biomarker testing wasn’t that common to do in squamous cell. Luckily, my oncologist took a chance and it saved my life.
I had 3 infusions on Immunotherapy and after that 3rd infusion, I knew I was dying. I was in a wheelchair, had obvious lumps all over, breaking bones, wearing diapers and sleeping 23 of 24 hours.
I was in my oncologist’s office, getting ready to tell him I was going on hospice when he had a surprise:
‘I had a targetable mutation called MET Amplification.’
He started me on Pfizer’s Crizotinib (Xalkori) and within 2 weeks, I was out of the wheelchair, lumps were gone and I was able to function almost normally.
Targetable Mutations in Squamous NSCLC is rare, but it happens – so push for it if you’re a patient. If you’re an oncologist, do the biomarker testing on your squamous patients.”
Quoting Cancer Precision Medicine Commons’s post:
“Cancer Biomarker Awareness Day (CBAD26) is coming. Patients can and should ask their care team about biomarker testing.
You can also read: Brian Grieb at COGC 2026: How Fast Can Testing Really Be? A Powerful Look at Rapid Precision Oncology
